Magda Babina

Dr. Magda Babina

Charité – Universitätsmedizin Berlin, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Nature
Verified
Journal Article
Closed access
PDF file
CHChung Chau Hon
Chung Chau Hon
JRJordan A. Ramilowski
Jordan A. Ramilowski
JHJayson Harshbarger
Jayson Harshbarger
NBNicolas Bertin
Nicolas Bertin
OROwen J. L. Rackham
Owen J. L. Rackham
AFAlistair R. R. Forrest
Alistair R. R. Forrest

21 August 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
TCThe FANTOM Consortium
The FANTOM Consortium
DRDerek de Rie
Derek de Rie
IAImad Abugessaisa
Imad Abugessaisa
Tanvir AlamTanvir Alam
Tanvir Alam
EAErik Arner
Erik Arner
MHMichiel J L de Hoon
Michiel J L de Hoon

29 August 2017 in Scientific Data
Verified
Journal Article
Open access
PDF file
SNShuhei Noguchi
Shuhei Noguchi
TATakahiro Arakawa
Takahiro Arakawa
SFShiro Fukuda
Shiro Fukuda
MFMasaaki Furuno
Masaaki Furuno
AHAkira Hasegawa
Akira Hasegawa
YHYoshihide Hayashizaki
Yoshihide Hayashizaki
In the FANTOM5 project, transcription initiation events across the human and mouse genomes were mapped at a single base-pair resolution and their frequencies were monitored by CAGE (Cap Analysis of Gene Expression) coupled with single-molecule sequencing. Approximately three thousands of samples, consisting of a variety of primary cells, tissues, cell lines, and time series samples during cell activation and development, were subjected to a uniform pipeline of CAGE data production. The analysis pipeline started by measuring RNA extracts to assess their quality, and continued to CAGE library production by using a robotic or a manual workflow, single molecule sequencing, and computational processing to generate frequencies of transcription initiation. Resulting data represents the consequence of transcriptional regulation in each analyzed state of mammalian cells. Non-overlapping peaks over the CAGE profiles, approximately 200,000 and 150,000 peaks for the human and mouse genomes, were identified and annotated to provide precise location of known promoters as well as novel ones, and to quantify their activities.

24 April 2014 in Blood
Verified
Journal Article
Open access
PDF file
EMEfthymios Motakis
Efthymios Motakis
SGSven Guhl
Sven Guhl
YIYuri Ishizu
Yuri Ishizu
MIMasayoshi Itoh
Masayoshi Itoh
HKHideya Kawaji
Hideya Kawaji
Magda BabinaMagda Babina
Magda Babina
Key Points: Generated a reference transcriptome for ex vivo, cultured, and stimulated mast cells, contrasted against a broad collection of primary cells. Identified BMPs as function-modulating factors for mast cells.

1 February 2001 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
BHB. M. Henz
B. M. Henz
MMM. Maurer
M. Maurer
ULU. Lippert
U. Lippert
MWM. Worm
M. Worm
Magda BabinaMagda Babina
Magda Babina
Until recently, mast cells have been viewed primarily as harmful because of their key role as effector cells of allergic and potentially lethal anaphylactic reactions. Their contribution to human health appeared instead to be limited to the elimination of parasites. There is, however, growing evidence for additional beneficial functions of mast cells, particularly regarding the initiation of acquired immune reactions. Thus, mast cells can phagocytize diverse particles, take up antigens, and express a number of receptors, particularly MHC class I and II antigens, ICAM‐1 and ‐3, CD43, CD80, CD86 and CD40L which allow them to interact with T and B lymphocytes. They can also secrete numerous cytokines that induce and enhance recruitment and functions of lymphocytes. Finally, there is good evidence that mast cells present e.g. pollen and bacterial antigens, respond to bacterial superantigens, but fail to react to endogenously produced antigens or superantigens. Mast cells can also activate B cells directly to produce IgE, but this activity and the ability to produce IL‐4 or IL‐13 is restricted primarily to basophil leukocytes and mucosal mast cells. Finally, recent evidence attributes a pivotal role to the cells in natural immunity to bacteria. There is also emerging evidence that mast cells can downmodulate the immune response. While these data require further clarification, the basic ability of mast cells to initiate innate and acquired immune reactions can no longer be questioned.

21 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJulia Minderjahn
Julia Minderjahn
ASAndreas Schmidt
Andreas Schmidt
AFAndreas Fuchs
Andreas Fuchs
RSRudolf Schill
Rudolf Schill
JRJohanna Raithel
Johanna Raithel
MRMichael Rehli
Michael Rehli
Establishing gene regulatory networks during differentiation or reprogramming requires master or pioneer transcription factors (TFs) such as PU.1, a prototype master TF of hematopoietic lineage differentiation. To systematically determine molecular features that control its activity, here we analyze DNA-binding in vitro and genome-wide in vivo across different cell types with native or ectopic PU.1 expression. Although PU.1, in contrast to classical pioneer factors, is unable to access nucleosomal target sites in vitro, ectopic induction of PU.1 leads to the extensive remodeling of chromatin and redistribution of partner TFs. De novo chromatin access, stable binding, and redistribution of partner TFs both require PU.1’s N-terminal acidic activation domain and its ability to recruit SWI/SNF remodeling complexes, suggesting that the latter may collect and distribute co-associated TFs in conjunction with the non-classical pioneer TF PU.1.